Acorda Therapeutics

From Wikipedia, the free encyclopedia - View original article

Acorda Therapeutics Inc.
TypePublic
Traded asNASDAQACOR FWBCDG
IndustryHealth care
Biotechnology
Founded1995 (1995)[1]
FoundersRon Cohen
HeadquartersArdsley, New York, United States
Key peopleRon Cohen
Andrew R. Blight
ProductsZanaflex
Ampyra
Qutenza
RevenueIncrease US$292.2 Million (FY 2011)[2]
Operating incomeIncrease US$35.1 Million (FY 2011)[2]
Net incomeIncrease US$30.6 Million (FY 2011)[2]
Total assetsIncrease US$379.5 Million (FY 2011)[2]
Total equityIncrease US$205.2 Million (FY 2011)[2]
Employees328 (February, 2012) [2]
WebsiteAcorda.com
 
Jump to: navigation, search
Acorda Therapeutics Inc.
TypePublic
Traded asNASDAQACOR FWBCDG
IndustryHealth care
Biotechnology
Founded1995 (1995)[1]
FoundersRon Cohen
HeadquartersArdsley, New York, United States
Key peopleRon Cohen
Andrew R. Blight
ProductsZanaflex
Ampyra
Qutenza
RevenueIncrease US$292.2 Million (FY 2011)[2]
Operating incomeIncrease US$35.1 Million (FY 2011)[2]
Net incomeIncrease US$30.6 Million (FY 2011)[2]
Total assetsIncrease US$379.5 Million (FY 2011)[2]
Total equityIncrease US$205.2 Million (FY 2011)[2]
Employees328 (February, 2012) [2]
WebsiteAcorda.com

Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.

History[edit]

Corporate governance[edit]

As of December 31, 2013, the members of the board of directors of Acorda Therapeutics were:[4] Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.

Products[edit]

Products on the market[edit]

Products under development[edit]

References[edit]

External links[edit]